Skip to main content

Table 4 Adverse events due to chemotherapy according to tomographic response to neoadjuvant chemotherapy (n = 53). Percentage values are calculated within groups

From: Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer

Adverse event (CTCAE 5.0)

With response (%)

Without response (%)

p-valuea

Neutropenia

Grade 0

10 (31.3)

4 (19.0)

0.582

Grade 1

1 (3.1)

2 (9.52)

Grade 2

8 (25.0)

8 (38.1)

Grade 3

11 (34.4)

5 (23.9)

Grade 4

2 (6.3)

2 (9.5)

Anemia

Grade 0

19 (35.8)

12 (22.6)

0.773

Grade 1

5 (9.4)

2 (3.8)

Grade 2

7 (13.2)

5 (9.4)

Grade 3

1 (1.9)

2 (3.8)

Thrombocytopenia

Grade 0

29 (90.6)

15 (71.42)

0.134

Grade 1

2 (6.2)

1 (4.8)

Grade 2

0 (0.0)

3 (14.3)

Grade 3

1 (3.1)

2 (9.5)

Nausea

Grade 0

19 (57.6)

11 (52.4)

0.953

Grade 1

9 (27.3)

7 (33.3)

Grade 2

4 (12.1)

3 (14.3)

Grade 3

1 (3.0)

0 (0.0)

Emesis

Grade 0

26 (81.2)

15 (71.4)

0.676

Grade 1

4 (12.5)

5 (23.8)

Grade 2

2 (6.3)

1 (4.8)

Diarrhea

Grade 0

27 (84.4)

20 (95.2)

0.781

Grade 1

4 (12.5)

1 (4.8)

Grade 2

1 (3.1)

0 (0.0)

Renal toxicity

Yes

1 (3.1)

0 (0.0)

1

No

31 (96.9)

21 (100.0)

Liver Toxicity

Yes

1 (3.1)

0 (0.0)

0.413

No

31 (96.9)

21 (100.0)

Peripheral

Grade 0

23 (71.9)

14 (66.7)

0.908

Neuropathy

Grade 1

5 (15.6)

3 (14.3)

Grade 2

4 (12.5)

4 (19.0)

  1. a Fisher exact test; CTCAE 5.0: Common Terminology Criteria for Adverse Events version 5.0